featured
Efficacy of Sotorasib vs Docetaxel for Previously Treated Non–Small Cell Lung Cancer With KRAS G12C Mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Lancet 2023 Mar 04;401(10378)733-746, AJ de Langen, ML Johnson, J Mazieres, AC Dingemans, G Mountzios, M Pless, J Wolf, M Schuler, H Lena, F Skoulidis, Y Yoneshima, SW Kim, H Linardou, S Novello, AJ van der Wekken, Y Chen, S Peters, E Felip, BJ Solomon, SS Ramalingam, C Dooms, CR Lindsay, CG Ferreira, N Blais, CC Obiozor, Y Wang, B Mehta, T Varrieur, G Ngarmchamnanrith, B Stollenwerk, D Waterhouse, L Paz-AresFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.